Fulcrum Therapeutics

169 articles about Fulcrum Therapeutics

• Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

  8/10/2021

  Fulcrum Therapeutics, Inc. today announced positive interim results from the ongoing single- and multiple-ascending dose (SAD and MAD) Phase 1 trial with FTX-6058 in healthy adult volunteers.

• Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET

  8/4/2021

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that its second quarter 2021 financial results will be released on Tuesday, August 10, 2021 before the U.S. financial markets open.

• 

  Positive Outcomes May Outweigh Failed Endpoint for Fulcrum's FSHD Drug Losmapimod

  6/24/2021

  Fulcrum achieved what the company is calling a clinical first. Data showed that using losmapimod slowed the progression of FSHD and demonstrated improved function in patients. 

• Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function

  6/24/2021

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced results from the company’s Phase 2b trial, ReDUX4, in people with facioscapulohumeral muscular dystrophy.

• Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC)

  6/21/2021

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced multiple presentations at the 28th Annual FSHD Society International Research Congress.

• Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

  5/12/2021

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the U.S. Food and Drug Administration has granted Fast Track designation to losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy.

• Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

  5/7/2021

  Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will present a corporate overview at the BofA Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 11:00 a.m. ET.

• Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

  5/6/2021

  – On track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) at virtual FSHD International Research Congress in June 2021 – – On track to report data from Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease in mid-2021 – – Conference call scheduled for 8:00 a.m. ET today –

• Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer

  5/6/2021

  Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced Christopher J. Morabito, M.D. has been appointed Chief Medical Officer, effective May 10, 2021. Dr. Morabito will oversee the development of Fulcrum’s lead programs in facioscapulohumeral dystrophy (FSHD) and select hemoglobinopathies,

• Fulcrum Therapeutics to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, May 6, 2021 at 8:00 a.m. ET

  4/29/2021

  Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2021 financial results will be released on Thursday, May 6, 2021 before the U.S. financial markets open.

• Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference

  4/9/2021

  Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today presented the medicinal chemistry strategy for FTX-6058 at the First Time Disclosure Session at the American Chemical Society (ACS) Spring 2021 National Meeting.

• Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development

  3/24/2021

  Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Judith A. Dunn, Ph.D. has been appointed President of Research and Development.

• Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference

  3/18/2021

  – Demonstrated Whole-Body MRI captures heterogeneity and provides key disease severity and progression information correlated with FSHD clinical endpoints – –  Demonstrated potential of FSHD-TUG and Emerald in-home assessments as accurate, low-burden clinical assessments of mobility for FSHD patients

• Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

  3/4/2021

  Fulcrum Therapeutics today provided a business update and reported financial results for the fourth quarter and full year of 2020.

• Fulcrum Therapeutics Announces CEO Transition

  3/4/2021

  Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Bryan E. Stuart, the company’s chief operating officer, will become Fulcrum’s president and chief executive officer and will be appointed to the Board of Directors.

• Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET

  2/26/2021

  Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2020 financial results will be released on Thursday, March 4, 2021 before the U.S. financial markets open.

• Fulcrum Therapeutics Recognizes Rare Disease Day 2021Theme of global unity highlights critical role of building communities of support for patients and families affected by rare diseases around the world

  2/26/2021

  Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the company’s recognition of Rare Disease Day 2021.

• Fulcrum Therapeutics to Participate in Upcoming Investor Conferences - Feb 19, 2021

  2/19/2021

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that management will participate in the following virtual investor conferences

• Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

  1/22/2021

  Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock at a public offering price of $11.00 per share, which includes 600,000 shares issued upon the exercise in full by the underwriters of their option to purcha

• Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock - Jan 20, 2021

  1/20/2021

  Fulcrum Therapeutics, Inc. announced that it has priced an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $11.00 per share, for total gross proceeds of $44.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Fulcrum.